|
1
|
Huang DP, Ho JH, Poon YF, Chew EC, Saw D,
Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell
line (NPC/HK1) from a differentiated squamous carcinoma of the
nasopharynx. Int J Cancer. 26:127–132. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee JH, Zhang J, Wei L and Yu SP:
Neurodevelopmental implications of the general anesthesia in
neonate and infants. Exp Neurol. 272:50–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee N, Harris J, Garden AS, Straube W,
Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et
al: Intensity-modulated radiation therapy with or without
chemotherapy for nasopharyngeal carcinoma: Radiation therapy
oncology group phase II trial 0225. J Clin Oncol. 27:3684–3690.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen L, Mao YP, Xie FY, Liu LZ, Sun Y,
Tian L, Tang LL, Lin AH, Li L and Ma J: The seventh edition of the
UICC/AJCC staging system for nasopharyngeal carcinoma is
prognostically useful for patients treated with intensity-modulated
radiotherapy from an endemic area in China. Radiother Oncol.
104:331–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frixen UH, Behrens J, Sachs M, Eberle G,
Voss B, Warda A, Löchner D and Birchmeier W: E-cadherin-mediated
cell-cell adhesion prevents invasiveness of human carcinoma cells.
J Cell Biol. 113:173–185. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Nat
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ying SY, Chang DC and Lin SL: The microRNA
(miRNA): Overview of the RNA genes that modulate gene function. Mol
Biotechnol. 38:257–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang N, Wang Q, Shen D, Sun X, Cao X and
Wu D: Downregulation of microRNA-122 promotes proliferation,
migration, and invasion of human hepatocellular carcinoma cells by
activating epithelial-mesenchymal transition. Onco Targets Ther.
9:2035–2047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qin H, Sha J, Jiang C, Gao X, Qu L, Yan H,
Xu T, Jiang Q and Gao H: miR-122 inhibits metastasis and
epithelial-mesenchymal transition of non-small-cell lung cancer
cells. Onco Targets Ther. 8:3175–3184. 2015.PubMed/NCBI
|
|
13
|
Watanabe M and Hatakeyama S: TRIM proteins
and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
|
|
14
|
Sato T, Takahashi H, Hatakeyama S, Iguchi
A and Ariga T: The TRIM-FLMN protein TRIM45 directly interacts with
RACK1 and negatively regulates PKC-mediated signaling pathway.
Oncogene. 34:1280–1291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanno Y, Watanabe M, Kimura T, Nonomura K,
Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell
marker for diagnosis of prostate cancer. Acta Histochem.
116:708–712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Yang H, Palmbos PL, Ney G, Detzler
TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, et al:
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates
radioresistance in pancreatic cancer cells. Cancer Res.
74:1778–1788. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aoki M and Fujishita T: Oncogenic Roles of
the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI
|
|
20
|
Grille SJ, Bellacosa A, Upson J,
Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and
Larue L: The protein kinase Akt induces epithelial mesenchymal
transition and promotes enhanced motility and invasiveness of
squamous cell carcinoma lines. Cancer Res. 63:2172–2178.
2003.PubMed/NCBI
|
|
21
|
Xu J, Li Z, Su Q, Zhao J and Ma J: TRIM29
promotes progression of thyroid carcinoma via activating P13K/AKT
signaling pathway. Oncol Rep. 37:1555–1564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang C, Wang H, Zhou L, Jiang T, Xu Y and
Xia L: MicroRNA-212 inhibits the metastasis of nasopharyngeal
carcinoma by targeting SOX4. Oncol Rep. 38:82–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toh Y and Nicolson GL: Identification and
characterization of metastasis-associated gene/protein 1 (MTA1).
Cancer Metastasis Rev. 33:837–842. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Birkedal-Hansen H, Moore WG, Bodden MK,
Windsor LJ, Birkedal-Hansen B, DeCarlo A and Engler JA: Matrix
metalloproteinases: A review. Crit Rev Oral Biol Med. 4:197–250.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Musso O, Théret N, Campion JP, Turlin B,
Milani S, Grappone C and Clément B: In situ detection of matrix
metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor
TIMP2 transcripts in human primary hepatocellular carcinoma and in
liver metastasis. J Hepatol. 26:593–605. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L: MicroRNA and Metastasis. Adv Cancer
Res. 132:165–207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ergün S, Ulasli M, Igci YZ, Igci M,
Kırkbes S, Borazan E, Balik A, Yumrutaş Ö, Camci C, Cakmak EA, et
al: The association of the expression of miR-122-5p and its target
ADAM10 with human breast cancer. Mol Biol Rep. 42:497–505. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and
Sun G: MiR-122 targets VEGFC in bladder cancer to inhibit tumor
growth and angiogenesis. Am J Transl Res. 8:3056–3066.
2016.PubMed/NCBI
|
|
30
|
Fristrup N, Birkenkamp-Demtröder K,
Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J,
Alvarez-Múgica M, Pan CC, Ulhøi BP, et al: Multicenter validation
of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers
in non-muscle-invasive bladder cancer. Am J Pathol. 182:339–349.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Glebov OK, Rodriguez LM, Soballe P,
DeNobile J, Cliatt J, Nakahara K and Kirsch IR: Gene expression
patterns distinguish colonoscopically isolated human aberrant crypt
foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev.
15:2253–2262. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Geara FB, Sanguineti G, Tucker SL, Garden
AS, Ang KK, Morrison WH and Peters LJ: Carcinoma of the nasopharynx
treated by radiotherapy alone: Determinants of distant metastasis
and survival. Radiother Oncol. 43:53–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schram FR and Ng PKL: What is Cancer? J
Crust Biol. 32:665–672. 2012. View Article : Google Scholar
|
|
34
|
Rao M, Zhu Y, Zhou Y, Cong X and Feng L:
MicroRNA-122 inhibits proliferation and invasion in gastric cancer
by targeting CREB1. Am J Cancer Res. 7:323–333. 2017.PubMed/NCBI
|
|
35
|
Qiao DD, Yang J, Lei XF, Mi GL, Li SL, Li
K, Xu CQ and Yang HL: Expression of microRNA-122 and microRNA-22 in
HBV-related liver cancer and the correlation with clinical
features. Eur Rev Med Pharmacol Sci. 21:742–747. 2017.PubMed/NCBI
|
|
36
|
Maierthaler M, Benner A, Hoffmeister M,
Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H and
Burwinkel B: Plasma miR-122 and miR-200 family are prognostic
markers in colorectal cancer. Int J Cancer. 140:176–187. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jingushi K, Kashiwagi Y, Ueda Y, Kitae K,
Hase H, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K:
High miR-122 expression promotes malignant phenotypes in ccRCC by
targeting occludin. Int J Oncol. 51:289–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ai L, Kim WJ, Alpay M, Tang M, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM and Brown
KD: TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu J, Welm B, Boucher KM, Ebbert MT and
Bernard PS: TRIM29 functions as a tumor suppressor in
nontumorigenic breast cells and invasive ER+ breast cancer. Am J
Pathol. 180:839–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
